The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus

Journal of Clinical Pharmacology

Volumn 57, Issue 11, 2017, Pages 1432-1443

  Sahasrabudhe, V ^a   Terra, S G ^a   Hickman, A ^a   Saur, D ^a   Shi, H ^a   O'Gorman, M ^a   Zhou, Z ^b   Cutler, D L ^b  

^a PFIZER INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

ertugliflozin; renal impairment; sodium glucose cotransporter 2; type 2 diabetes mellitus

Indexed keywords

ERTUGLIFLOZIN; GLUCOSE; GLUCURONIDE; HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; 5-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-1-HYDROXYMETHYL-6,8-DIOXABICYCLO(3.2.1)OCTANE-2,3,4-TRIOL; ANTIDIABETIC AGENT; FUSED HETEROCYCLIC RINGS; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY SURFACE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG TOLERABILITY; ESTIMATED GLOMERULAR FILTRATION RATE; EXCRETION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE LEVEL; GLUCOSE URINE LEVEL; GLUCOSURIA; HALF LIFE TIME; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MEASUREMENT; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; RENAL CLEARANCE; SEVERE RENAL IMPAIRMENT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNBOUND FRACTION; URINE SAMPLING; CLINICAL TRIAL; GLOMERULUS FILTRATION RATE; KIDNEY; KIDNEY FAILURE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

AGED; BLOOD GLUCOSE; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85023624136     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.955     Document Type: Article

References (27)

1. de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532–2539.
2. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014;64:510–533.
3. Wu B, Bell K, Stanford A, et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 2007-2012. BMJ Open Diabetes Res Care. 2016;4:e000154.
4. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733–794.
5. Abdul-Ghani MA, Norton L, DeFronzo RA. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol. 2015;309:F889–F900.
6. Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19:721–728.
7. Eldor RR, Golm G, Huyck S, et al. Effect of ertugliflozin plus sitagliptin on glycemic control vs. either treatment alone in subjects with T2DM inadequately controlled with metformin. Paper presented at: 76th Scientific Sessions of the American Diabetes Association (ADA); June 10-14, 2016; New Orleans, LA.
8. Lauring BER, Liu J, DaGogo-Jack S, et al. Efficacy and safety of ertugliflozin in subjects with T2DM inadequately controlled on the dual combination of metformin and sitagliptin: the VERTIS SITA2 trial. Paper presented at: 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD); September 12-16, 2016; Munich, Germany.
9. Amin NB, Wang X, Mitchell JR, et al. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab. 2015;17:805–808.
10. Amin NB, Wang X, Jain SM, et al. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015;17:591-598.
11. Gilbert RE. SGLT-2 inhibition in patients with kidney disease. Diabetes Metab. 2014;40:S23–S27.
12. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463–473.
13. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–971.
14. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369–384.
15. Kalgutkar AS, Tugnait M, Zhu T, et al. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos. 2011;39:1609–1619.
16. Miao Z, Nucci G, Amin N, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013;41:445–456.
17. Margaillan G, Rouleau M, Fallon JK, et al. Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues. Drug Metab Dispos. 2015;43:611–619.
18. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254.
19. European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/02/WC500200841.pdf. Accessed June 9, 2017.
20. American Diabetes Association. Executive summary: Standards of medical care in diabetes—2012. Diabetes Care. 2012;35 (suppl 1):S4–S10.
21. Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016;12:73–81.
22. Devineni D, Curtin CR, Marbury TC, et al. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Ther. 2015;37:610–628.e614.
23. National Kidney Association. Frequently asked questions about GFR estimates. https://www.kidney.org/sites/default/files/12-10-4004_FAQ-ABE.pdf. Accessed June 9, 2017.
24. Kumar V, Sahasrabudhe V, Matschke K, et al. Lack of a pharmacokinetic interaction between ertugliflozin and sitagliptin or metformin in healthy subjects. Paper presented at: 2016 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT); March 8-12, 2016; San Diego, CA.
25. Kumar V, Sahasrabudhe V, Liang Y, et al. Effect of rifampin on the pharmacokinetics of ertugliflozin in healthy subjects. Paper presented at: 2016 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT); March 8-12, 2016; San Diego, CA.
26. Sahasrabudhe V, Kumar V, Matschke K, et al. Lack of a clinically meaningful pharmacokinetic interaction between ertugliflozin and glimepiride or simvastatin in healthy subjects. Paper presented at: 2016 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT); March 8-12, 2016; San Diego, CA.
27. Raje S, Callegari E, Sahasrabudhe V, et al. Determination of absolute oral availability and fraction absorbed of ertugliflozin using a novel microtracer approach. Paper presented at: 2016 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT); March 8-12, 2016; San Diego, CA.